Previous close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 35.00 |
Expiry date | 2024-06-21 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 51 |
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
FOSTER CITY, Calif., June 17, 2024--Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies